Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study of the Safety and Efficacy of a Wearable Device (CLS UF) That Delivers Continuous Administration of Glucose to Recirculated Peritoneal Dialysis Fluid for the Purpose of Ultrafiltration in Patients With Congestive Heart Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patient, 18-80 years of age.~* Prevalent PD patients with CHF with cardio-renal syndrome type II, on stable ultrafiltration, for more than two months, treated with PD based UF according to German national guidelines.~  * Therapy resistance of pharmacologic therapy: resistant hypervolemia with ascites, pleural fluid and pulmonary edema~ * Recurrent hospitalization with cardiac decompensation, ≥ 2 occasions during the last six months~ * Isolated failure of the right heart chamber~* Treatment based on night time APD therapy combined with a day time long dwell.~* Obtained written consent to participate in the study.~Exclusion Criteria:~* End stage renal disease requiring dialysis.~* Malignant disease.~* On-going infection.~* Diabetes mellitus.~* HIV and/or hepatitis positive.~* Pregnancy.~* Breastfeeding women.~* Participation in other clinical trials within one month before inclusion.~* Abdominal hernia.~* Cardiac diseases other than left ventricular heart failure, biventricular heart failure or isolated right heart chamber failure, with volume overload.~* Any immune deficiency.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Device: CLS UF (Type: EXPERIMENTAL): The purpose of CLS UF is ultrafiltration and drain of excess fluid in patients with congestive heart failure. The function of the device is to extra corporeally recirculate profiled glucose based PD fluid in a system and maintain glucose levels by adding extra glucose, to an adjustable and constant level, in order to maintain a stable ultrafiltration.

Based on this trial design, predict the completion outcome and termination type (if applicable).